Claims for Patent: 5,650,503

Summary for Patent: 5,650,503

Title:	Genetic construct of which protein coding DNA comprises introns and is designed for protein production in transgenic animals
Abstract:	Proteinaceous products can be produced by transgenic animals having genetic constructs integrated into their genome. The construct comprises a 5\'-flanking sequence from a mammalian milk protein gene (such as beta-lactoglobulin) and DNA coding for a heterologous protein other than the milk protein (for example a serin protease such as alpha.sub.1 -antitrypsin or a blood factor such as Factor VIII or IX). The protein-coding DNA comprises at least one, but not all, of the introns naturally occurring in a gene coding for the heterologous protein. The 5\'-flanking sequence is sufficient to drive expression of the heterologous protein.
Inventor(s):	Archibald; Alan Langskill (Edinburgh, GB), Clark; Anthony John (Lasswade, GB), Harris; Stephen (Edinburgh, GB), McClenaghan; Margaret (Edinburgh, GB), Simons; Jonathan Paul (Edinburgh, GB), Whitelaw; Christopher Bruce Alexander (Edinburgh, GB)
Assignee:	PPL Therapeutics (Scotland) Limited (Edinburgh, GB6)
Application Number:	08/359,854
Patent Claims:	1. An isolated and purified genetic construct comprising (a) a 5'-flanking sequence from a mammalian milk protein gene and (b) DNA coding for human alpha.sub.1 -antitrypsin, which comprises all of the complete introns, naturally occurring in the gene coding for human alpha.sub.1 -antitrypsin except for the complete naturally occurring intron I, counting from the 5' end of the gene encoding alpha.sub.1 -antitrypsin, wherein the naturally occurring intron I of said gene coding for human alpha.sub.1 -antitrypsin is absent in its entirety, and wherein the 5'-flanking sequence is operably linked to said DNA coding for human alpha.sub.1 -antitrypsin and controls and directs expression of the DNA encoding alpha.sub.1 -antitrypsin, and wherein said construct when present in the germline of a female transgenic non-human placental mammal, expresses alpha.sub.1 -antitrypsin in the mammary gland so that alpha.sub.1 -antitrypsin is present in the milk of said mammal, at levels greater than is achieved by expression of a corresponding intron-less construct. 2. A construct as claimed in claim 1, wherein the milk protein gene is a .beta.-lactoglobulin gene. 3. An isolated and purified genetic construct comprising (a) a 5'-flanking sequence from a mammalian .beta.-lactoglobulin gene, and (b) DNA coding for human alpha.sub.1 -antitrypsin, which comprises all of the complete introns, naturally occurring in the gene coding for human alpha.sub.1 -antitrypsin except for the complete naturally occurring intron I, counting from the 5' end of the gene encoding alpha.sub.1 -antitrypsin, wherein the naturally occurring intron I of said gene coding for human alpha.sub.1 -antitrypsin is absent in its entirety, wherein the 5'-flanking sequence is operably linked to said DNA coding for human alpha.sub.1 -antitrypsin and controls and directs expression of the DNA encoding alpha.sub.1 -antitrypsin, wherein said construct when present in the germline of a female transgenic non-human placental mammal, expresses alpha.sub.1 -antitrypsin in the mammary gland so that alpha.sub.1 -antitrypsin is present in the milk of said mammal, at levels greater than is achieved by expression of a corresponding intron-less construct, and wherein said 5'-flanking sequence is an upstream region of the .beta.-lactoglobulin transcription start site consisting of the SphI-BgllI 800 base pair fragment of pSS1tgSpDELTA-AvaII, or a fragment that retains the functional properties of the SphI-BgllI 800 base pair fragment of pSS1tgSpDELTA-AvaII. 4. A construct as claimed in claim 3, wherein the human alpha.sub.1 -antitrypsin is expressed at a level at least eight fold greater than is achieved by expression of a corresponding intron-less construct. 5. A construct as claimed in claim 3, wherein the human alpha.sub.1 -antitrypsin is expressed at a level at least one hundred fold greater than is achieved by expression of a corresponding intron-less construct. 6. An isolated and purified genetic construct, comprising (a) a 5'-flanking sequence from a mammalian .beta.-lactoglobulin gene, and (b) DNA coding for human alpha.sub.1 -antitrypsin, which comprises all of the, complete introns, naturally occurring in the gene coding for human alpha.sub.1 -antitrypsin except for the complete naturally occurring intron I, counting from the 5' end of the gene encoding alpha.sub.1 -antitrypsin, wherein the naturally occurring intron I of said gene coding for human alpha.sub.1 -antitrypsin is absent in its entirety, wherein the 5'-flanking sequence is operably linked to said DNA coding for human alpha.sub.1 -antitrypsin and controls and directs expression of the DNA encoding alpha.sub.1 -antitrypsin, wherein said construct when present in the germline of a female transgenic non-human placental mammal, expresses alpha.sub.1 -antitrypsin in the mammary gland so that alpha.sub.1 -antitrypsin is present in the milk of said mammal, at levels greater than is achieved by expression of a corresponding intron-less construct, and wherein said 5'-flanking sequence is an upstream region of the .beta.-lactoglobulin transcription start site consisting of the 4.2 kilobase pair SaII-SphI DNA fragment isolated from the 5' flanking sequences of the .beta.-lactoglobulin gene or a fragment that retains the functional properties of the 4.2 kilobase pair SaII-SphI DNA fragment. 7. A construct as claimed in claim 6, wherein the human alpha.sub.1 -antitrypsin is expressed at a level at least eight fold greater than is achieved by expression of a corresponding intron-less construct. 8. A construct as claimed in claim 6, wherein the human alpha.sub.1 -antitrypsin is expressed at a level at least one hundred fold greater than is achieved by expression of a corresponding intron-less construct. 9. A vector, other than a chromosome, in which the genetic construct as claimed in claim 1 has been inserted. 10. An isolated and purified genetic construct comprising (a) a 5'-flanking sequence from a mammalian milk protein gene and (b) DNA coding for human factor IX which comprises, counting from the 5' end, the first, but only the first, complete intron, naturally occurring in the gene encoding human factor IX, and wherein the 5'-flanking sequence is operably linked to said DNA coding for human factor IX and controls and directs expression of the DNA encoding human factor IX, and wherein said construct, when present in the germline of a female transgenic non-human placental mammal, expresses human factor IX in the mammary gland so that human factor IX is present in the milk of said mammal. 11. A construct as claimed in claim 10, wherein the milk protein gene is a .beta.-lactoglobulin gene. 12. An isolated and purified genetic construct, comprising (a) a 5'-flanking sequence from a mammalian .beta.-lactoglobulin gene, and (b) DNA coding for human factor IX which comprises, counting from the 5' end, the first, but only the first, complete intron, naturally occurring in the gene encoding human factor IX, wherein the 5'-flanking sequence is operably linked to said DNA coding for human factor IX and controls and directs expression of the DNA encoding human factor IX, wherein said construct, when present in the germline of a female transgenic non-human placental mammal, expresses human factor IX in the mammary gland so that human factor IX is present in the milk of said mammal, and wherein said 5'-flanking sequence is an upstream region of the .beta.-lactoglobulin transcription start site consisting of the SphI-BgllI 800 base pair fragment of pSS1tgSpDELTA-AvaII, or a fragment that retains the functional properties of the SphI-BgllI 800 base pair fragment of pSS1tgSpDELTA-AvaII. 13. An isolated and purified genetic construct, comprising (a) a 5'-flanking sequence from a mammalian .beta.-lactoglobulin gene, and (b) DNA coding for human factor IX which comprises, counting from the 5' end, the first, but only the first, complete intron, naturally occurring in the gene encoding human factor IX, wherein the 5'-flanking sequence is operably linked to said DNA coding for human factor IX and controls and directs expression of the DNA encoding human factor IX, wherein said construct, when present in the germline of a female transgenic non-human placental mammal, expresses human factor IX in the mammary gland so that human factor IX is present in the milk of said mammal, and wherein said 5'-flanking sequence is an upstream region of the .beta.-lactoglobulin transcription start site consisting of the 4.2 kilobase pair SalI-SphI DNA fragment isolated from the 5' flanking sequences of the .beta.-lactoglobulin gene or a fragment that retains the functional properties of the 4.2 kilobase pair SalI-SphI DNA fragment. 14. A vector, other than a chromosome, in which the genetic construct as claimed in claim 10 has been inserted.

Details for Patent 5,650,503

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2008-11-11
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2008-11-11
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2008-11-11